enVVeno Medical Corp also files under NVNO, HIJI; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Duhay Francis | Director | Sell(S) | 11 | $11.21 | $123 |
| Jun 11, 2026 | Duhay Francis | Director | Sell(S) | 140 | $10.31 | $1K |
| Mar 12, 2026 | Duhay Francis | Director | Sell(S) | 140 | $11.52 | $2K |
| Dec 16, 2025 | Alavi Hamed | Chief Technology Officer | Other(J) | 50K | — | $0 |
| Dec 16, 2025 | Berman Robert Andrew | Chief Executive Officer, Director | Other(J) | 200K | — | $0 |
| Dec 16, 2025 | Glickman Marc H. | SVP & Chief Medical Officer | Other(J) | 100K | — | $0 |
| Dec 11, 2025 | Jenusaitis Matthew | Director | Grant(A) | 136K | — | $0 |
| Dec 11, 2025 | Gray Robert | Director | Grant(A) | 136K | — | $0 |
| Dec 11, 2025 | Duhay Francis | Director | Sell(S) | 5K | $0.36 | $2K |
| Dec 11, 2025 | Duhay Francis | Director | Grant(A) | 136K | — | $0 |
| Dec 11, 2025 | Shrivastava Sanjay | Director | Grant(A) | 136K | — | $0 |
| Sep 15, 2025 | Duhay Francis | Director | Sell(S) | 5K | $0.83 | $4K |
| May 19, 2025 | Bright Jennifer | Chief Financial Officer | Grant(A) | 350K | — | $0 |
| Dec 31, 2024 | Gray Robert | Director | Buy(P) | 4K | $2.94 | $10K |
| Dec 31, 2024 | Duhay Francis | Director | Buy(P) | 81K | $3.07 | $250K |
| Dec 24, 2024 | Shrivastava Sanjay | Director | Buy(P) | 5K | $2.90 | $16K |
| Dec 19, 2024 | Jenusaitis Matthew | Director | Buy(P) | 10K | $2.53 | $24K |
| Dec 19, 2024 | Berman Robert Andrew | Chief Executive Officer, Director | Buy(P) | 12K | $2.55 | $31K |
| Dec 18, 2024 | Berman Robert Andrew | Chief Executive Officer, Director | Grant(A) | 200K | — | $0 |
| Dec 18, 2024 | Gray Robert | Director | Grant(A) | 20K | — | $0 |
| Dec 18, 2024 | Shrivastava Sanjay | Director | Grant(A) | 20K | — | $0 |
| Dec 18, 2024 | Alavi Hamed | Chief Technology Officer | Grant(A) | 75K | — | $0 |
| Dec 18, 2024 | Glickman Marc H. | SVP & Chief Medical Officer | Grant(A) | 75K | — | $0 |
| Dec 18, 2024 | Jenusaitis Matthew | Director | Grant(A) | 20K | — | $0 |
| Dec 18, 2024 | Duhay Francis | Director | Grant(A) | 20K | — | $0 |
| Mar 13, 2024 | Alavi Hamed | Chief Technology Officer | Option exercise(M) | 8K | — | $0 |
| Mar 13, 2024 | Alavi Hamed | Chief Technology Officer | Sell(S) | 8K | $6.22 | $52K |
| Mar 13, 2024 | Alavi Hamed | Chief Technology Officer | Option exercise(M) | 8K | $3.59 | $30K |
| Dec 5, 2023 | Duhay Francis | Director | Grant(A) | 14K | — | $0 |
| Dec 5, 2023 | Glickman Marc H. | SVP & Chief Medical Officer | Grant(A) | 100K | — | $0 |
| Dec 5, 2023 | Gray Robert | Director | Grant(A) | 14K | — | $0 |
| Dec 5, 2023 | Jenusaitis Matthew | Director | Grant(A) | 14K | — | $0 |
| Dec 5, 2023 | Shrivastava Sanjay | Director | Grant(A) | 14K | — | $0 |
| Dec 5, 2023 | Glynn Craig | Chief Financial Officer | Grant(A) | 75K | — | $0 |
| Dec 5, 2023 | Alavi Hamed | Chief Technology Officer | Grant(A) | 100K | — | $0 |
| Dec 5, 2023 | Berman Robert Andrew | Chief Executive Officer, Director | Grant(A) | 300K | — | $0 |
| Nov 30, 2022 | Jenusaitis Matthew | Director | Grant(A) | 8K | — | $0 |
| Nov 30, 2022 | Shrivastava Sanjay | Director | Grant(A) | 8K | — | $0 |
| Nov 30, 2022 | Gray Robert | Director | Grant(A) | 8K | — | $0 |
| Nov 30, 2022 | Duhay Francis | Director | Grant(A) | 8K | — | $0 |
| Sep 13, 2022 | Jenusaitis Matthew | Director | Option exercise(M) | 1K | — | $0 |
| Sep 13, 2022 | Gray Robert | Director | Option exercise(M) | 1K | — | — |
| Sep 13, 2022 | Gray Robert | Director | Option exercise(M) | 1K | — | $0 |
| Sep 13, 2022 | Jenusaitis Matthew | Director | Option exercise(M) | 1K | — | — |
| Aug 16, 2022 | Duhay Francis | Director | Buy(P) | 8K | $6.14 | $48K |
| Jun 30, 2022 | Shrivastava Sanjay | Director | Buy(P) | 1K | $3.85 | $4K |
| Jun 27, 2022 | Berman Robert Andrew | Chief Executive Officer, Director | Buy(P) | 3K | $3.80 | $10K |
| Nov 30, 2021 | Berman Robert Andrew | Chief Executive Officer, Director | Grant(A) | 200K | — | — |
| Nov 30, 2021 | Shrivastava Sanjay | Director | Grant(A) | 7K | — | $0 |
| Nov 30, 2021 | Jenusaitis Matthew | Director | Grant(A) | 7K | — | $0 |
| Nov 30, 2021 | Duhay Francis | Director | Grant(A) | 7K | — | $0 |
| Nov 30, 2021 | Gray Robert | Director | Grant(A) | 7K | — | $0 |
| Nov 30, 2021 | Glynn Craig | Chief Financial Officer | Grant(A) | 50K | — | — |
| Nov 30, 2021 | Glynn Craig | Chief Financial Officer | Grant(A) | 126K | — | $0 |
| Nov 30, 2021 | Glickman Marc H. | SVP & Chief Medical Officer | Grant(A) | 100K | — | — |
| Nov 30, 2021 | Glickman Marc H. | SVP & Chief Medical Officer | Grant(A) | 266K | — | $0 |
| Nov 30, 2021 | Berman Robert Andrew | Chief Executive Officer, Director | Grant(A) | 350K | — | $0 |
| Nov 19, 2021 | Berman Robert Andrew | CEO, Director | Buy(P) | 2K | $7.43 | $15K |
| Nov 16, 2021 | Shrivastava Sanjay | Director | Option exercise(M) | 388 | — | $0 |
| Nov 16, 2021 | Berman Robert Andrew | CEO | Buy(P) | 2K | $7.87 | $16K |
| Nov 16, 2021 | Shrivastava Sanjay | Director | Option exercise(M) | 388 | — | — |
| Sep 13, 2021 | Jenusaitis Matthew | Director | Option exercise(M) | 1K | — | — |
| Sep 13, 2021 | Jenusaitis Matthew | Director | Option exercise(M) | 1K | — | $0 |
| Sep 13, 2021 | Gray Robert | Director | Option exercise(M) | 1K | — | — |
| Sep 13, 2021 | Gray Robert | Director | Option exercise(M) | 1K | — | $0 |
| Aug 25, 2021 | Jenusaitis Matthew | Director | Buy(P) | 1K | $7.70 | $10K |
| Jun 16, 2021 | Gray Robert | Director | Buy(P) | 2K | $6.25 | $13K |
| May 21, 2021 | Glickman Marc H. | SVP & Chief Medical Officer | Buy(P) | 2K | $5.90 | $9K |
| May 18, 2021 | Berman Robert Andrew | Chief Executive Officer, Director | Buy(P) | 3K | $5.47 | $16K |
| May 17, 2021 | Duhay Francis | Director | Buy(P) | 9K | $5.33 | $51K |
| Feb 18, 2021 | Gray Robert | Director | Grant(A) | 6K | — | $0 |
| Feb 18, 2021 | Glickman Marc H. | SVP & CMO | Grant(A) | 406K | — | $0 |
| Feb 18, 2021 | Berman Robert Andrew | Chief Executive Officer | Grant(A) | 838K | — | $0 |
| Feb 18, 2021 | Shrivastava Sanjay | Director | Grant(A) | 6K | — | $0 |
| Feb 18, 2021 | Jenusaitis Matthew | Director | Grant(A) | 6K | — | $0 |
| Feb 18, 2021 | Duhay Francis | Director | Grant(A) | 6K | — | $0 |
| Feb 18, 2021 | Glynn Craig | Chief Financial Officer | Grant(A) | 324K | — | $0 |
| Aug 21, 2020 | Biodyne Holding, S.A. | Insider | Sell(S) | 75K | $0.38 | $29K |
| Aug 20, 2020 | Biodyne Holding, S.A. | Insider | Sell(S) | 75K | $0.27 | $20K |
| Aug 19, 2020 | Biodyne Holding, S.A. | Insider | Sell(S) | 50K | $0.30 | $15K |
| Aug 18, 2020 | Biodyne Holding, S.A. | Insider | Sell(S) | 50K | $0.34 | $17K |
| Aug 14, 2020 | Biodyne Holding, S.A. | Insider | Sell(S) | 50K | $0.31 | $16K |
| Aug 3, 2020 | Biodyne Holding, S.A. | Insider | Sell(S) | 70K | $0.32 | $22K |
| Jul 31, 2020 | Biodyne Holding, S.A. | Insider | Sell(S) | 5K | $0.34 | $2K |
| Jul 30, 2020 | Biodyne Holding, S.A. | Insider | Sell(S) | 25K | $0.32 | $8K |
| Jul 21, 2020 | Biodyne Holding, S.A. | Insider | Sell(S) | 50K | $0.45 | $23K |
| Jul 20, 2020 | Biodyne Holding, S.A. | Insider | Sell(S) | 150K | $0.43 | $65K |
| Jul 18, 2020 | Berman Robert Andrew | CEO | Grant(A) | 1.1M | — | $0 |
| Jul 18, 2020 | Glynn Craig | Chief Financial Officer | Grant(A) | 4K | — | $0 |
| Jul 18, 2020 | Glickman Marc H. | SVP & CMO | Grant(A) | 1.0M | — | $0 |
| Jul 18, 2020 | Shrivastava Sanjay | Director | Grant(A) | 100K | — | $0 |
| Jul 18, 2020 | Shrivastava Sanjay | Director | Grant(A) | 63K | — | $0 |
| Jul 18, 2020 | Duhay Francis | Director | Grant(A) | 100K | — | $0 |
| Jul 18, 2020 | Duhay Francis | Director | Grant(A) | 63K | — | $0 |
| Jul 18, 2020 | Gray Robert | Director | Grant(A) | 100K | — | $0 |
| Jul 18, 2020 | Jenusaitis Matthew | Director | Grant(A) | 63K | — | $0 |
| Jul 18, 2020 | Gray Robert | Director | Grant(A) | 63K | — | $0 |
| Jul 18, 2020 | Berman Robert Andrew | CEO | Other(J) | 1.1M | — | $0 |
| Jul 18, 2020 | Jenusaitis Matthew | Director | Grant(A) | 100K | — | $0 |
| Jul 18, 2020 | Berman Robert Andrew | CEO | Grant(A) | 1.0M | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: enVVeno Medical Corp, SEC CIK 0001661053. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under HJLI and shows every filing by that issuer (also filed as NVNO, HIJI).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-15. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for HJLI